Latest On Stoke Therapeutics, Inc (STOK):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-04 17:05 EST | News | Stoke Therapeutics GAAP EPS of -$0.53 beats by $0.15, revenue of $5.15M beats by $1.65M | N/A |  |
| 2023-05-01 14:11 EST | News | Stoke Therapeutics upgraded to neutral at BoA on Dravet candidate | N/A | |
| 2023-04-26 22:19 EST | News | Stoke Therapeutics a buy at Canaccord on platform for genetic diseases | N/A | |
| 2023-04-25 22:00 EST | News | Stoke stock rises after UK regulator nod to start trial of eye disorder drug | N/A | |
| 2023-03-15 17:15 EST | News | Stoke gets FDA nod to use higher dose of epilepsy drug in ongoing trial | N/A | |
| 2023-03-06 19:36 EST | News | Stoke Therapeutics GAAP EPS of -$0.65 beats by $0.05, revenue of $3.27M beats by $0.41M | N/A | |
| 2023-02-12 09:04 EST | News | Stoke Therapeutics Looks Unfairly Valued | N/A | |
| 2022-11-28 18:27 EST | News | Buy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet Syndrome | N/A | |
| 2022-11-14 15:38 EST | News | Stoke Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $2.91M beats by $0.19M | N/A | |
| 2022-11-14 15:37 EST | News | Stoke Therapeutics drops 27% after early data for anti-seizure medicine | N/A | |
| 2022-08-09 08:23 EST | News | Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M | N/A | |
| 2022-05-10 14:29 EST | News | Stoke Therapeutics GAAP EPS of -$0.66 misses by $0.98, revenue of $3M misses by $34.5M | N/A | |
| 2022-03-10 22:22 EST | News | Stoke Therapeutics GAAP EPS of -$0.66 misses by $0.04 | N/A | |
| 2022-01-31 23:13 EST | News | Stoke Therapeutics initiated Buy at Jefferies on potential of RNA platform | N/A | |
| 2022-01-25 02:45 EST | News | Stoke Therapeutics (STOK) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference | N/A | |
| 2021-12-03 21:14 EST | News | Stoke Therapeutics shares data from Phase 1/2a trial for STK-001 in Dravet syndrome | N/A | |
| 2021-12-01 09:31 EST | News | Warning: STOK is at high risk of performing badly | N/A | |
| 2021-12-01 09:31 EST | News | Stoke Therapeutics (STOK) Investor Presentation -Slideshow | N/A | |
| 2021-11-23 08:45 EST | News | Stoke Therapeutics up 14% following J.P. Morgan upgrade to overweight | N/A | |
| 2021-11-08 19:21 EST | News | Stoke Therapeutics EPS misses by $0.02 | N/A | |
| 2021-09-22 07:07 EST | News | Stoke Therapeutics posts interim results from early-stage STK-001 Dravet syndrome study | N/A | |
| 2021-08-10 12:23 EST | News | Stoke Therapeutics EPS misses by $0.12 | N/A | |
| 2021-03-30 13:19 EST | News | Stoke Therapeutics gets MHRA greenlight for early-stage Dravet syndrome study | N/A | |
| 2021-03-11 20:54 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-11 12:29 EST | Analyst Rating | The Analyst Target Price has increased from $63.75 to $65.38. | Buy | |
| 2021-03-11 00:51 EST | Earnings Estimate | An EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-03-11 00:51 EST | Analyst Rating | The Analyst Target Price has increased from $60.38 to $63.75. | Buy | |
| 2021-03-11 00:51 EST | Earnings Estimate | An EPS average of -$2.12 is estimated for the 2022 year. | Sell | |
| 2021-03-10 04:53 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-07 14:56 EST | News | Sizing Up Stoke Therapeutics | N/A | |
| 2021-02-11 08:36 EST | Analyst Rating | The Analyst Target Price has increased from $59.5 to $60.38. | Neutral | |
| 2021-02-10 19:01 EST | News | Stoke cut to neutral at Wedbush seeking a ‘better entry point’ | N/A | |
| 2021-01-29 08:37 EST | Analyst Rating | The Analyst Target Price has increased from $57.63 to $59.5. | Neutral | |
| 2021-01-15 08:37 EST | Analyst Rating | The Analyst Target Price has increased from $56.5 to $57.63. | Neutral | |
| 2020-12-29 08:37 EST | Analyst Rating | The Analyst Target Price has increased from $54.13 to $56.5. | Neutral | |
| 2020-12-16 13:07 EST | Analyst Rating | The Analyst Target Price has increased from $49.13 to $54.13. | Neutral | |
| 2020-12-14 08:52 EST | Analyst Rating | The Analyst Target Price has increased from $48.13 to $49.13. | Neutral | |
| 2020-12-14 08:12 EST | News | Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap | N/A | |
| 2020-11-26 21:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-20 03:45 EST | News | Stoke Therapeutics prices $97.5M public offering | N/A | |
| 2020-11-19 00:23 EST | News | Stoke Therapeutics -2.7% AH, proposes public offering | N/A | |
| 2020-11-17 05:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 05:28 EST | Analyst Rating | The Analyst Target Price has increased from $47.13 to $48.13. | Buy | |
| 2020-11-14 21:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 13:26 EST | Earnings Estimate | An EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-13 13:26 EST | Analyst Rating | The Analyst Target Price has increased from $41.5 to $47.13. | Buy | |
| 2020-11-13 10:25 EST | News | Stoke Therapeutics EPS in-line | N/A | |
| 2020-11-08 00:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-04 18:01 EST | Insider Trade | Huw M. Nash has directly disposed of 2,536 shares and currently holds 0 shares. | Sell | |
About Stoke Therapeutics, Inc (STOK):
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
General
- Name Stoke Therapeutics, Inc
- Symbol STOK
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 79
- Fiscal Year EndDecember
- IPO Date2019-06-19
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.stoketherapeutics.com
View More
Valuation
- Trailing PE 21.65
- Price/Book (Most Recent Quarter) 6.47
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.80
- Next Year EPS Estimate -$2.10
- Next Quarter EPS Estimate -$0.44
- Return on Assets -13%
- Return on Equity -20%
- Earnings Per Share -$11.44
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 1.78 billion
- EBITDA -22302000
- PE Ratio -7.4
- Analyst Target Price $65.38
- Book Value Per Share $7.14
View More
Share Statistics
- Shares Outstanding 36.66 million
- Shares Float 12.64 million
- % Held by Insiders 170%
- % Held by Institutions 98.06%
- Shares Short 3.3 million
- Shares Short Prior Month 3.37 million
- Short Ratio 27.54
- Short % of Float 21%
- Short % of Shares Outstanding 9%
View More
Technicals
- 52 Week High $71.58
- 52 Week Low $17.55
- 50 Day Moving Average 58.62
- 200 Day Moving Average 48.97
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Stoke Therapeutics, Inc (STOK) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Stoke Therapeutics, Inc (STOK) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-09 | $N/A | -$0.42 | -$0.42 | 0.92% |
| 2020-09-30 | 2020-11-12 | $N/A | -$0.41 | -$0.43 | 4.58% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.39 | -$0.36 | -8.33% |
| 2020-03-31 | 2020-05-15 | $N/A | -$0.34 | -$0.37 | 8.87% |
| 2019-12-31 | 2020-03-23 | $N/A | -$0.09 | -$0.30 | 69.63% |
| 2019-09-30 | 2019-11-12 | $N/A | -$0.26 | -$0.28 | 5.83% |
| 2019-06-30 | 2019-08-14 | $N/A | -$1.54 | -$1.63 | 5.39% |
Stoke Therapeutics, Inc (STOK) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 8.9 million | N/A | N/A | 7.22 million | 7.09 million |
| Income Before Tax | -14.56 million | N/A | N/A | -11.04 million | -10.16 million |
| Selling General Administrative | 5.68 million | N/A | N/A | 4.52 million | 3.98 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -14.35 million | N/A | N/A | -11.54 million | -11.07 million |
| Operating Income | -14.59 million | N/A | N/A | -11.74 million | -11.07 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | 15000 | N/A | N/A | 22000 | 908000 |
| Net Income From Continuing Operations | -14.56 million | N/A | N/A | -11.04 million | -10.16 million |
| Net Income Applicable to Common Shares | -14.56 million | -13.68 million | -12.96 million | N/A | -10.16 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -269000 | -81000 | -610000 | N/A | N/A |
| Change to Liabilities | 610000 | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -269000 | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | 673000 | 369000 | 198000 | N/A | N/A |
| Change to Operating Activities | -80000 | N/A | N/A | N/A | N/A |
| Change in Cash | -10.47 million | -9.36 million | -11.18 million | N/A | N/A |
| Total Cash from Operating Activities | -10.87 million | -9.65 million | -10.77 million | N/A | N/A |
| Depreciation | 234000 | 224000 | 193000 | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -360000 | N/A | N/A | N/A | N/A |
| Change to Net Income | 2.05 million | N/A | N/A | N/A | N/A |
| Capital Expenditures | 269000 | 81000 | 610000 | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 11.85 million | N/A | N/A | 6.5 million | 4.32 million |
| Total Stockholder Equity | 286.08 million | N/A | N/A | 214.34 million | 224.43 million |
| Other Current Liabilities | N/A | N/A | N/A | 54000 | N/A |
| Total Assets | 297.93 million | N/A | N/A | 220.84 million | 228.75 million |
| Common Stock | 4000 | 3000 | 3000 | N/A | 3000 |
| Other Current Assets | 6.62 million | 378000 | N/A | N/A | N/A |
| Retained Earnings | -110.28 million | -95.72 million | -82.03 million | -69.07 million | -58.04 million |
| Other Liabilities | N/A | 665000 | 1.01 million | N/A | 221000 |
| Other Assets | N/A | 205000 | 205000 | N/A | 205000 |
| Cash | 287.31 million | N/A | N/A | 211.29 million | 222.47 million |
| Total Current Liabilities | 11.43 million | 6.74 million | N/A | 5.46 million | 4.1 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 2.68 million | 4.27 million | 4.47 million | N/A | 2.51 million |
| Total Current Assets | 293.93 million | 195.46 million | N/A | 215.77 million | 226.03 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 286.08 million | 192.54 million | 203.4 million | N/A | 224.43 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 11.43 million | 1.1 million | N/A | 1.78 million | 751000 |
Stoke Therapeutics, Inc (STOK) Chart:
Stoke Therapeutics, Inc (STOK) News:
Below you will find a list of latest news for Stoke Therapeutics, Inc (STOK) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Stoke Therapeutics, Inc (STOK) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-04-17 | 2.5 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-04-17 | 5 | 0 | CALL | 0 | 0 | 325.35 | TRUE | 0 | 0 |
| 2025-04-17 | 7.5 | 0.05 | CALL | 0 | 7 | 179.94 | FALSE | 0 | 0 |
| 2025-04-17 | 10 | 0.33 | CALL | 0 | 26 | 600.86 | FALSE | 0 | 0 |
| 2025-04-17 | 12.5 | 0.05 | CALL | 1 | 3 | 282.03 | FALSE | 0.05 | 0 |
| 2025-04-17 | 15 | 0 | CALL | 0 | 0 | 1244.33 | FALSE | 0 | 0 |
| 2025-04-17 | 17.5 | 0 | CALL | 0 | 0 | 1318.49 | FALSE | 0 | 0 |
| 2025-04-17 | 20 | 0 | CALL | 0 | 0 | 1379.76 | FALSE | 0 | 0 |
| 2025-04-17 | 2.5 | 0 | PUT | 0 | 0 | 466.18 | FALSE | 0 | 0 |
| 2025-04-17 | 5 | 0.15 | PUT | 0 | 126 | 459.53 | FALSE | 0 | 0 |
| 2025-04-17 | 7.5 | 0.95 | PUT | 0 | 260 | 80.7 | TRUE | 0 | 0 |
| 2025-04-17 | 10 | 0 | PUT | 0 | 0 | 507 | TRUE | 0 | 0 |
| 2025-04-17 | 12.5 | 0 | PUT | 0 | 0 | 597.09 | TRUE | 0 | 0 |
| 2025-04-17 | 15 | 0 | PUT | 0 | 0 | 721.8 | TRUE | 0 | 0 |
| 2025-04-17 | 17.5 | 0 | PUT | 0 | 0 | 721.1 | TRUE | 0 | 0 |
| 2025-04-17 | 20 | 0 | PUT | 0 | 0 | 622.42 | TRUE | 0 | 0 |
| 2025-05-16 | 2.5 | 0 | CALL | 0 | 0 | 335.21 | TRUE | 0 | 0 |
| 2025-05-16 | 5 | 6.7 | CALL | 0 | 0 | 230.07 | TRUE | 0 | 0 |
| 2025-05-16 | 7.5 | 0.14 | CALL | 0 | 93 | 120.85 | FALSE | 0 | 0 |
| 2025-05-16 | 10 | 0.35 | CALL | 0 | 91 | 93.26 | FALSE | 0 | 0 |
| 2025-05-16 | 12.5 | 0.2 | CALL | 0 | 65 | 214.82 | FALSE | 0 | 0 |
| 2025-05-16 | 15 | 0.05 | CALL | 0 | 5 | 476.52 | FALSE | 0 | 0 |
| 2025-05-16 | 17.5 | 0.25 | CALL | 0 | 4 | 505 | FALSE | 0 | 0 |
| 2025-05-16 | 20 | 1.6 | CALL | 0 | 5 | 528.52 | FALSE | 0 | 0 |
| 2025-05-16 | 22.5 | 1.3 | CALL | 0 | 1 | 548.49 | FALSE | 0 | 0 |
| 2025-05-16 | 25 | 0.05 | CALL | 1 | 2 | 197.65 | FALSE | 0.05 | 0 |
| 2025-05-16 | 30 | 0.4 | CALL | 0 | 1 | 594.69 | FALSE | 0 | 0 |
| 2025-05-16 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-05-16 | 5 | 0.4 | PUT | 2 | 96 | 130.33 | FALSE | 0.4 | 0 |
| 2025-05-16 | 7.5 | 3.35 | PUT | 0 | 463 | 103 | TRUE | 0 | 0 |
| 2025-05-16 | 10 | 2.5 | PUT | 0 | 3 | 184.87 | TRUE | 0 | 0 |
| 2025-05-16 | 12.5 | 6.7 | PUT | 0 | 24 | 175.71 | TRUE | 0 | 0 |
| 2025-05-16 | 15 | 4.11 | PUT | 0 | 1 | 216.94 | TRUE | 0 | 0 |
| 2025-05-16 | 17.5 | 0 | PUT | 0 | 0 | 243.49 | TRUE | 0 | 0 |
| 2025-05-16 | 20 | 0 | PUT | 0 | 0 | 247.03 | TRUE | 0 | 0 |
| 2025-05-16 | 22.5 | 0 | PUT | 0 | 0 | 265.55 | TRUE | 0 | 0 |
| 2025-05-16 | 25 | 0 | PUT | 0 | 0 | 301.17 | TRUE | 0 | 0 |
| 2025-05-16 | 30 | 0 | PUT | 0 | 0 | 329.17 | TRUE | 0 | 0 |
| 2025-08-15 | 2.5 | 6.2 | CALL | 0 | 0 | 517.36 | TRUE | 0 | 0 |
| 2025-08-15 | 5 | 0 | CALL | 0 | 0 | 139.27 | TRUE | 0 | 0 |
| 2025-08-15 | 7.5 | 1.5 | CALL | 0 | 7 | 70.43 | FALSE | 0 | 0 |
| 2025-08-15 | 10 | 0.3 | CALL | 0 | 34 | 99.72 | FALSE | 0 | 0 |
| 2025-08-15 | 12.5 | 0.8 | CALL | 0 | 3 | 228.69 | FALSE | 0 | 0 |
| 2025-08-15 | 15 | 2.5 | CALL | 0 | 10 | 162.61 | FALSE | 0 | 0 |
| 2025-08-15 | 17.5 | 0 | CALL | 0 | 0 | 262.38 | FALSE | 0 | 0 |
| 2025-08-15 | 20 | 1.5 | CALL | 0 | 1 | 274.69 | FALSE | 0 | 0 |
| 2025-08-15 | 22.5 | 0 | CALL | 0 | 0 | 285.14 | FALSE | 0 | 0 |
| 2025-08-15 | 25 | 0.95 | CALL | 0 | 1 | 294.19 | FALSE | 0 | 0 |
| 2025-08-15 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-08-15 | 5 | 0 | PUT | 0 | 0 | 127.4 | FALSE | 0 | 0 |
| 2025-08-15 | 7.5 | 2.36 | PUT | 0 | 557 | 80.7 | TRUE | 0 | 0 |
| 2025-08-15 | 10 | 2.7 | PUT | 0 | 1 | 119.33 | TRUE | 0 | 0 |
| 2025-08-15 | 12.5 | 4.3 | PUT | 0 | 0 | 126.73 | TRUE | 0 | 0 |
| 2025-08-15 | 15 | 0 | PUT | 0 | 0 | 139.36 | TRUE | 0 | 0 |
| 2025-08-15 | 17.5 | 0 | PUT | 0 | 0 | 151.25 | TRUE | 0 | 0 |
| 2025-08-15 | 20 | 0 | PUT | 0 | 0 | 167.98 | TRUE | 0 | 0 |
| 2025-08-15 | 22.5 | 0 | PUT | 0 | 0 | 144.6 | TRUE | 0 | 0 |
| 2025-08-15 | 25 | 0 | PUT | 0 | 0 | 164.12 | TRUE | 0 | 0 |
| 2025-09-19 | 2.5 | 0 | CALL | 0 | 0 | 158.84 | TRUE | 0 | 0 |
| 2025-09-19 | 5 | 4.1 | CALL | 0 | 4 | 128.09 | TRUE | 0 | 0 |
| 2025-09-19 | 7.5 | 0 | CALL | 0 | 0 | 97.25 | FALSE | 0 | 0 |
| 2025-09-19 | 10 | 1.26 | CALL | 0 | 2 | 96.04 | FALSE | 0 | 0 |
| 2025-09-19 | 12.5 | 0 | CALL | 0 | 0 | 106.82 | FALSE | 0 | 0 |
| 2025-09-19 | 15 | 0 | CALL | 0 | 0 | 116.66 | FALSE | 0 | 0 |
| 2025-09-19 | 17.5 | 0.38 | CALL | 0 | 13 | 111.59 | FALSE | 0 | 0 |
| 2025-09-19 | 20 | 0.34 | CALL | 0 | 1 | 242.46 | FALSE | 0 | 0 |
| 2025-09-19 | 2.5 | 0 | PUT | 0 | 0 | 283.9 | FALSE | 0 | 0 |
| 2025-09-19 | 5 | 0 | PUT | 0 | 0 | 115.16 | FALSE | 0 | 0 |
| 2025-09-19 | 7.5 | 1.4 | PUT | 0 | 13 | 88.6 | TRUE | 0 | 0 |
| 2025-09-19 | 10 | 0 | PUT | 0 | 0 | 110.85 | TRUE | 0 | 0 |
| 2025-09-19 | 12.5 | 0 | PUT | 0 | 0 | 110.73 | TRUE | 0 | 0 |
| 2025-09-19 | 15 | 0 | PUT | 0 | 0 | 125.23 | TRUE | 0 | 0 |
| 2025-09-19 | 17.5 | 0 | PUT | 0 | 0 | 136.14 | TRUE | 0 | 0 |
| 2025-09-19 | 20 | 0 | PUT | 0 | 0 | 147.92 | TRUE | 0 | 0 |
| 2025-11-21 | 2.5 | 0 | CALL | 0 | 0 | 117.21 | TRUE | 0 | 0 |
| 2025-11-21 | 5 | 0 | CALL | 0 | 0 | 112.38 | TRUE | 0 | 0 |
| 2025-11-21 | 7.5 | 0 | CALL | 0 | 0 | 86.32 | FALSE | 0 | 0 |
| 2025-11-21 | 10 | 0 | CALL | 0 | 0 | 101.46 | FALSE | 0 | 0 |
| 2025-11-21 | 12.5 | 0 | CALL | 0 | 0 | 97.36 | FALSE | 0 | 0 |
| 2025-11-21 | 15 | 0 | CALL | 0 | 0 | 102.32 | FALSE | 0 | 0 |
| 2025-11-21 | 17.5 | 0 | CALL | 0 | 0 | 113.04 | FALSE | 0 | 0 |
| 2025-11-21 | 2.5 | 0.3 | PUT | 0 | 10 | 164.92 | FALSE | 0 | 0 |
| 2025-11-21 | 5 | 0 | PUT | 0 | 0 | 104.94 | FALSE | 0 | 0 |
| 2025-11-21 | 7.5 | 1.9 | PUT | 0 | 1 | 78.54 | TRUE | 0 | 0 |
| 2025-11-21 | 10 | 0 | PUT | 0 | 0 | 113.96 | TRUE | 0 | 0 |
| 2025-11-21 | 12.5 | 0 | PUT | 0 | 0 | 112.97 | TRUE | 0 | 0 |
| 2025-11-21 | 15 | 0 | PUT | 0 | 0 | 108.76 | TRUE | 0 | 0 |
| 2025-11-21 | 17.5 | 0 | PUT | 0 | 0 | 118.31 | TRUE | 0 | 0 |
Latest STOK Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:58 PM EST | 13 | $10.47 |
| Jun 13, 2022 7:59 PM EST | 60 | $10.47 |
| Jun 13, 2022 7:59 PM EST | 20 | $10.47 |
| Jun 13, 2022 7:59 PM EST | 41 | $10.47 |
| Jun 13, 2022 7:59 PM EST | 15 | $10.47 |
Stoke Therapeutics, Inc (STOK) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm |
| 2019-04-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1623526/000000000019007260/0000000000-19-007260-index.htm |
| 2019-05-14 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1623526/000000000019008485/0000000000-19-008485-index.htm |
| 2019-06-03 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1623526/000000000019009270/0000000000-19-009270-index.htm |
| 2019-06-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1623526/000000000019009719/0000000000-19-009719-index.htm |
| 2020-07-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1623526/000000000020006449/0000000000-20-006449-index.htm |
| 2019-07-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1623526/000092963819000658/0000929638-19-000658-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1623526/000092963820000333/0000929638-20-000333-index.htm |
| 2019-03-26 | DRS | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1623526/000095012319002845/0000950123-19-002845-index.htm |
| 2019-04-30 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1623526/000095012319003688/0000950123-19-003688-index.htm |
| 2019-04-30 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1623526/000095012319003690/0000950123-19-003690-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1623526/000110465920021017/0001104659-20-021017-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000114420419031374/0001144204-19-031374-index.htm |
| 2019-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000114420419032095/0001144204-19-032095-index.htm |
| 2019-05-23 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1623526/000119312519155301/0001193125-19-155301-index.htm |
| 2019-05-23 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1623526/000119312519155321/0001193125-19-155321-index.htm |
| 2019-06-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1623526/000119312519163789/0001193125-19-163789-index.htm |
| 2019-06-07 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1623526/000119312519167576/0001193125-19-167576-index.htm |
| 2019-06-07 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1623526/000119312519167579/0001193125-19-167579-index.htm |
| 2019-06-11 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1623526/000119312519170268/0001193125-19-170268-index.htm |
| 2019-06-12 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1623526/000119312519171310/0001193125-19-171310-index.htm |
| 2019-06-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1623526/000119312519171314/0001193125-19-171314-index.htm |
| 2019-06-14 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1623526/000119312519173255/0001193125-19-173255-index.htm |
| 2019-06-14 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1623526/000119312519173266/0001193125-19-173266-index.htm |
| 2019-06-19 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1623526/000119312519175848/0001193125-19-175848-index.htm |
| 2019-06-18 | S-1MEF | Registration adding securities to prior Form S-1 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1623526/000119312519175863/0001193125-19-175863-index.htm |
| 2019-06-19 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1623526/000119312519176488/0001193125-19-176488-index.htm |
| 2019-07-01 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1623526/000119312519186323/0001193125-19-186323-index.htm |
| 2019-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312519220567/0001193125-19-220567-index.htm |
| 2019-12-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312519308649/0001193125-19-308649-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312520005877/0001193125-20-005877-index.htm |
| 2020-03-23 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1623526/000119312520082470/0001193125-20-082470-index.htm |
| 2020-04-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312520108110/0001193125-20-108110-index.htm |
| 2020-04-21 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1623526/000119312520113542/0001193125-20-113542-index.htm |
| 2020-04-21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1623526/000119312520113561/0001193125-20-113561-index.htm |
| 2020-05-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312520139879/0001193125-20-139879-index.htm |
| 2020-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312520160684/0001193125-20-160684-index.htm |
| 2020-07-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312520189990/0001193125-20-189990-index.htm |
| 2020-07-10 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1623526/000119312520191098/0001193125-20-191098-index.htm |
| 2020-07-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1623526/000119312520193961/0001193125-20-193961-index.htm |
| 2020-08-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312520221818/0001193125-20-221818-index.htm |
| 2020-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312520226962/0001193125-20-226962-index.htm |
| 2020-10-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000119312520265127/0001193125-20-265127-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm |
| 2020-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120021312/0001209191-20-021312-index.htm |
| 2020-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120021314/0001209191-20-021314-index.htm |
| 2020-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120021317/0001209191-20-021317-index.htm |
| 2020-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120021319/0001209191-20-021319-index.htm |
| 2020-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120021321/0001209191-20-021321-index.htm |
| 2020-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120021322/0001209191-20-021322-index.htm |
| 2020-04-15 | 3/A | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120024540/0001209191-20-024540-index.htm |
| 2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm |
| 2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm |
| 2020-05-26 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120032142/0001209191-20-032142-index.htm |
| 2020-05-26 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120032146/0001209191-20-032146-index.htm |
| 2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm |
| 2020-06-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034721/0001209191-20-034721-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034723/0001209191-20-034723-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034729/0001209191-20-034729-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034731/0001209191-20-034731-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034732/0001209191-20-034732-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034735/0001209191-20-034735-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034737/0001209191-20-034737-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm |
| 2020-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm |
| 2020-08-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm |
| 2020-08-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm |
| 2020-09-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm |
| 2020-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm |
| 2020-10-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm |
| 2020-10-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm |
| 2020-11-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm |
| 2020-11-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2019-06-13 | CERT | Certification | https://www.sec.gov/Archives/edgar/data/1623526/000135445719000309/0001354457-19-000309-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000149315219009407/0001493152-19-009407-index.htm |
| 2019-06-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm |
| 2019-06-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1623526/000149315219009851/0001493152-19-009851-index.htm |
| 2019-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm |
| 2019-11-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm |
| 2019-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm |
| 2019-11-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1623526/000149315220002386/0001493152-20-002386-index.htm |
| 2019-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1623526/000156459019032126/0001564590-19-032126-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000156459019042621/0001564590-19-042621-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1623526/000156459019042891/0001564590-19-042891-index.htm |
| 2020-03-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000156459020012112/0001564590-20-012112-index.htm |
| 2020-03-23 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1623526/000156459020012202/0001564590-20-012202-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000156459020025636/0001564590-20-025636-index.htm |
| 2020-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1623526/000156459020025637/0001564590-20-025637-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1623526/000156459020038587/0001564590-20-038587-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1623526/000156459020038905/0001564590-20-038905-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013623/0001567619-19-013623-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013624/0001567619-19-013624-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013625/0001567619-19-013625-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013626/0001567619-19-013626-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013627/0001567619-19-013627-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013628/0001567619-19-013628-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013629/0001567619-19-013629-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013630/0001567619-19-013630-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013631/0001567619-19-013631-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013632/0001567619-19-013632-index.htm |
| 2019-06-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013633/0001567619-19-013633-index.htm |
| 2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013662/0001567619-19-013662-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm |
| 2019-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919018220/0001567619-19-018220-index.htm |
| 2019-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919018221/0001567619-19-018221-index.htm |
| 2019-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919018222/0001567619-19-018222-index.htm |
| 2019-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919018223/0001567619-19-018223-index.htm |
| 2019-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919018224/0001567619-19-018224-index.htm |
| 2019-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919018225/0001567619-19-018225-index.htm |
| 2019-11-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919021770/0001567619-19-021770-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1623526/000156761919021771/0001567619-19-021771-index.htm |
| 2014-11-24 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1623526/000162352614000001/0001623526-14-000001-index.htm |
| 2018-11-02 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1623526/000162352618000002/0001623526-18-000002-index.htm |
| 2019-06-18 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1623526/999999999519001367/9999999995-19-001367-index.htm |
| 2020-07-20 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1623526/999999999520001866/9999999995-20-001866-index.htm |
| 2019-06-03 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1623526/999999999719005333/9999999997-19-005333-index.htm |
| 2019-06-13 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1623526/999999999719005455/9999999997-19-005455-index.htm |
Stoke Therapeutics, Inc (STOK) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Stoke Therapeutics, Inc (STOK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 170%Institutional Ownership: 9806%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-03-02 | Huw M. Nash | COO & CBO | Sell | 15,995.00 | 26.37 | 421,852.13 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm |
| 2020-06-01 | Huw M. Nash | COO & CBO | Sell | 500.00 | 27.48 | 13,742.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm |
| 2020-07-01 | Huw M. Nash | COO & CBO | Sell | 3,800.00 | 23.15 | 87,967.72 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm |
| 2020-07-07 | Huw M. Nash | COO & CBO | Sell | 913.00 | 22.41 | 20,456.86 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm |
| 2020-07-16 | Huw M. Nash | COO & CBO | Sell | 1,900.00 | 25.06 | 47,614.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm |
| 2020-08-03 | Huw M. Nash | COO & CBO | Sell | 5,700.00 | 24.73 | 140,943.33 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm |
| 2020-08-28 | Huw M. Nash | COO & CBO | Sell | 2,081.00 | 30.00 | 62,430.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm |
| 2020-09-01 | Huw M. Nash | COO & CBO | Sell | 700.00 | 28.71 | 20,097.63 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm |
| 2020-09-08 | Huw M. Nash | COO & CBO | Sell | 30,718.00 | 30.00 | 921,540.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm |
| 2020-09-09 | Huw M. Nash | COO & CBO | Sell | 17,201.00 | 30.00 | 516,030.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm |
| 2020-10-01 | Huw M. Nash | COO & CBO | Sell | 2,300.00 | 34.86 | 80,182.60 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm |
| 2020-11-02 | Huw M. Nash | COO & CBO | Sell | 2,536.00 | 37.98 | 96,324.89 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm |
| 2020-07-07 | Robin A. Walker | Chief Legal Officer, CCO & Sec | Sell | 941.00 | 22.50 | 21,172.50 | 0.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm |
| 2020-11-02 | Stephen J Tulipano | CFO | Sell | 14,445.00 | 37.86 | 546,909.37 | 1,002.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2020-06-01 | Barry Ticho | Chief Medical Officer | Buy | 131,147.00 | 0.60 | 78,688.20 | 131,147.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm |
| 2020-03-31 | Gene Liau | EVP Research & Preclinical Dev | Buy | 7,500.00 | 0.60 | 4,500.00 | 13,500.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm |
| 2020-05-22 | Gene Liau | EVP Research & Preclinical Dev | Sell | 7,500.00 | 30.00 | 225,000.00 | 13,500.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm |
| 2020-06-01 | Gene Liau | EVP Research & Preclinical Dev | Sell | 1,230.00 | 27.48 | 33,801.51 | 13,500.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm |
| 2020-10-13 | Gene Liau | EVP Research & Preclinical Dev | Sell | 1,649.00 | 40.00 | 65,960.00 | 13,500.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm |
| 2020-10-16 | Gene Liau | EVP Research & Preclinical Dev | Sell | 5,851.00 | 40.00 | 234,041.76 | 13,500.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm |
| 2020-10-19 | Gene Liau | EVP Research & Preclinical Dev | Sell | 7,225.00 | 38.42 | 277,585.95 | 13,500.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm |
| 2020-06-01 | Gene Liau | EVP Research & Preclinical Dev | Sell | 7,875.00 | 26.91 | 211,920.98 | 14,730.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm |
| 2020-10-13 | Gene Liau | EVP Research & Preclinical Dev | Buy | 1,649.00 | 0.60 | 989.40 | 15,149.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm |
| 2020-11-02 | Stephen J Tulipano | CFO | Sell | 20,155.00 | 36.79 | 741,448.03 | 15,447.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2020-03-02 | Huw M. Nash | COO & CBO | Sell | 33,148.00 | 25.66 | 850,697.01 | 15,995.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm |
| 2019-06-21 | Apple Tree Partners IV, L.P. | 10% Share Holder | Buy | 1,388,889.00 | 18.00 | 25,000,002.00 | 16,786,713.00 | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm |
| 2019-06-21 | Seth Loring Harrison | Director | Buy | 1,388,889.00 | 18.00 | 25,000,002.00 | 16,786,713.00 | https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm |
| 2020-11-04 | Stephen J Tulipano | CFO | Sell | 16,941.00 | 40.03 | 678,085.55 | 16,929.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2020-09-09 | Huw M. Nash | COO & CBO | Buy | 17,201.00 | 2.19 | 37,670.19 | 17,201.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm |
| 2020-06-01 | Barry Ticho | Chief Medical Officer | Sell | 365.00 | 27.98 | 10,212.70 | 172,662.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm |
| 2020-06-01 | Barry Ticho | Chief Medical Officer | Sell | 1,000.00 | 27.17 | 27,174.00 | 173,027.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm |
| 2020-06-01 | Barry Ticho | Chief Medical Officer | Buy | 42,880.00 | 2.19 | 93,907.20 | 174,027.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm |
| 2020-07-16 | Huw M. Nash | COO & CBO | Buy | 1,900.00 | 2.19 | 4,161.00 | 1,900.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm |
| 2020-10-16 | Gene Liau | EVP Research & Preclinical Dev | Buy | 5,851.00 | 0.60 | 3,510.60 | 19,351.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm |
| 2020-10-19 | Gene Liau | EVP Research & Preclinical Dev | Sell | 24,775.00 | 37.64 | 932,578.07 | 20,725.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm |
| 2020-08-28 | Huw M. Nash | COO & CBO | Buy | 2,081.00 | 2.19 | 4,557.39 | 2,081.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm |
| 2020-05-22 | Gene Liau | EVP Research & Preclinical Dev | Buy | 7,500.00 | 0.60 | 4,500.00 | 21,000.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm |
| 2020-06-01 | Huw M. Nash | COO & CBO | Buy | 2,107.00 | 2.19 | 4,614.33 | 2,107.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm |
| 2020-06-01 | Gene Liau | EVP Research & Preclinical Dev | Sell | 10,895.00 | 25.82 | 281,314.35 | 22,605.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm |
| 2020-10-01 | Huw M. Nash | COO & CBO | Sell | 3,400.00 | 34.33 | 116,717.92 | 2,300.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm |
| 2020-11-03 | Stephen J Tulipano | CFO | Buy | 1,732.00 | 4.48 | 7,759.36 | 2,334.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2020-11-02 | Huw M. Nash | COO & CBO | Sell | 3,164.00 | 36.59 | 115,785.00 | 2,536.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm |
| 2020-09-08 | Huw M. Nash | COO & CBO | Buy | 30,718.00 | 2.19 | 67,272.42 | 30,718.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm |
| 2020-06-01 | Gene Liau | EVP Research & Preclinical Dev | Buy | 20,000.00 | 2.19 | 43,800.00 | 33,500.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm |
| 2019-06-19 | RTW INVESTMENTS, LP | 10% Share Holder | Buy | 555,556.00 | 18.00 | 10,000,008.00 | 3,355,466.00 | https://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm |
| 2020-11-04 | Stephen J Tulipano | CFO | Buy | 33,268.00 | 4.48 | 149,040.64 | 33,870.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2019-10-01 | RTW INVESTMENTS, LP | 10% Share Holder | Buy | 31,560.00 | 21.96 | 693,029.20 | 3,387,026.00 | https://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm |
| 2019-10-30 | RTW INVESTMENTS, LP | 10% Share Holder | Buy | 41,438.00 | 28.79 | 1,193,004.16 | 3,428,464.00 | https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm |
| 2019-10-31 | RTW INVESTMENTS, LP | 10% Share Holder | Buy | 18,747.00 | 28.15 | 527,658.69 | 3,447,211.00 | https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm |
| 2019-11-01 | RTW INVESTMENTS, LP | 10% Share Holder | Buy | 8,598.00 | 28.61 | 245,950.09 | 3,455,809.00 | https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm |
| 2019-11-08 | RTW INVESTMENTS, LP | 10% Share Holder | Sell | 16,434.00 | 28.70 | 471,631.15 | 3,544,248.00 | https://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm |
| 2020-11-02 | Stephen J Tulipano | CFO | Buy | 35,000.00 | 4.48 | 156,800.00 | 35,602.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2019-11-04 | RTW INVESTMENTS, LP | 10% Share Holder | Buy | 104,873.00 | 29.24 | 3,066,843.09 | 3,560,682.00 | https://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm |
| 2020-07-01 | Huw M. Nash | COO & CBO | Buy | 3,800.00 | 2.19 | 8,322.00 | 3,800.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm |
| 2020-10-19 | Gene Liau | EVP Research & Preclinical Dev | Buy | 30,497.00 | 0.60 | 18,298.20 | 43,997.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm |
| 2020-10-19 | Gene Liau | EVP Research & Preclinical Dev | Buy | 1,503.00 | 2.19 | 3,291.57 | 45,500.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm |
| 2020-03-02 | Huw M. Nash | COO & CBO | Buy | 42,779.00 | 2.19 | 93,686.01 | 49,103.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm |
| 2020-06-01 | Huw M. Nash | COO & CBO | Sell | 1,607.00 | 27.08 | 43,521.26 | 500.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm |
| 2019-12-16 | Edward M. MD Kaye | CEO | Buy | 50,000.00 | 0.60 | 30,000.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm |
| 2020-08-03 | Huw M. Nash | COO & CBO | Buy | 5,700.00 | 2.19 | 12,483.00 | 5,700.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm |
| 2020-09-01 | Huw M. Nash | COO & CBO | Buy | 5,700.00 | 2.19 | 12,483.00 | 5,700.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm |
| 2020-10-01 | Huw M. Nash | COO & CBO | Buy | 5,700.00 | 2.19 | 12,483.00 | 5,700.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm |
| 2020-11-02 | Huw M. Nash | COO & CBO | Buy | 5,700.00 | 2.19 | 12,483.00 | 5,700.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm |
| 2020-11-04 | Stephen J Tulipano | CFO | Sell | 11,111.00 | 41.42 | 460,214.29 | 5,818.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2019-12-20 | Gene Liau | EVP Research & Preclinical Dev | Buy | 6,000.00 | 0.60 | 3,600.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm |
| 2020-11-02 | Stephen J Tulipano | CFO | Sell | 400.00 | 38.44 | 15,374.00 | 602.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2020-11-03 | Stephen J Tulipano | CFO | Sell | 1,732.00 | 39.84 | 68,997.51 | 602.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2020-11-04 | Stephen J Tulipano | CFO | Sell | 5,216.00 | 41.97 | 218,909.78 | 602.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm |
| 2020-03-02 | Huw M. Nash | COO & CBO | Buy | 6,324.00 | 0.40 | 2,529.60 | 6,324.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm |
| 2020-09-01 | Huw M. Nash | COO & CBO | Sell | 5,000.00 | 27.60 | 138,015.00 | 700.00 | https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm |